Tissue Therapies (ASX: TIS) has been placed into an ASX trading halt while it prepares a proposed capital raising.
The halt will last until the earlier of an announcement being made available to the market, or the opening of trade on Friday 22 February.
Tissue Therapies is currently waiting on the European Medicines Agency to complete its discussions to assign a procedural start date for the award of a CE Mark to its VitroGro® ECM treatment for hard to heal wounds.
It also plans to lodge the U.S. FDA clinical trial applications in the next few months.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.